Balazs Odler

MD PhD | Nephrologist with interest in kidney autoimmunity at the @MedUniGraz | ERA YNP Board Member | views my own 🇪🇺

[Balazs Odler @odlerb]

Just published in @Kidney_Int - The impact of PLEX and GC on early kidney function changes in AAV. (https://t.co/r4MS4tziJO) This analysis provides another important piece of the “PLEX puzzle”.
Many thanks to my co-authors, the PIs and especially to @AKronbichler and David Jayne.

[YNP of ERA @ynptweets]

👉🏻 Check out this month snapshot summary about CAKUT disease in adult patients

https://t.co/JLdV3Y4CiB

✍️Charlotte Hammett is the YNP author

Post prepared by @jt_nephrology
@NDTsocial
@ERAkidney

[YNP of ERA @ynptweets]

Apply to be a board member of the YNP! 👇🏻

[YNP of ERA @ynptweets]

🪨 Kidney stones: Time to nephrologists to reclaim the field?

👀Check out our latest post with 10 tips on work-up and management of CKD
patients with nephrolithiasis.

Gerlineke Hawkins-van der Cingel is the YNP author 
🧵by @jt_nephrology
@CKJsocial @ERAkidney

[Andreas Kronbichler @AKronbichler]

I am glad to work together with leading experts in the field of rare kidney diseases! Together these diseases are common! Thank you @GlomCon

[YNP of ERA @ynptweets]

🙌🏻 Check out this month snapshot summary about pharmacologial differences between man and woman with CKD

https://t.co/lgfHJOXXzy

@SoleneLaville is the YNP author

Post prepared by @jt_nephrology

@ERAkidney @NDTsocial

[YNP of ERA @ynptweets]

Apply now! Such a great opportunity! 👇🏻

[YNP of ERA @ynptweets]

1/ 🧬 CRISPR and gene editing for kidney diseases: Where do we stand in 2025?
A review on how CRISPR and other gene editing tools are redefining what’s possible in nephrology — from fixing mutations to regenerating kidney tissue.

@Violadmb is the YNP author
🧵 by @jt_nephrology
@CKJsocial @ERAkidney

[Balazs Odler @odlerb]

ANCA-negative pauci-immune glomerulonephritis must be one of the most challenging fields in vasculitis. In this commentary in @KIReports, we discuss some open questions on this topic.

https://t.co/LmOzPjrrds

[ANZ Vasculitis Society, '26 Vasculitis Wkshop host @anzvasc]

We’re calling on researchers, clinicians, and educators—share your work with the global vasculitis community!
Submit your abstract by 19 September 2025—don’t miss your chance to be part of this exciting event!
https://t.co/gyCj4F3Ik1
#VasculitisMelbourne2026

[ERA - European Renal Association @ERAkidney]

📢 Join us at the YNP & EFIM joint e-seminar: *Cardiorenal Syndrome – Perspectives from Nephrology and Internal Medicine*
📅 Wednesday, May 14, 2025, 5:00 PM (CEST)
Register now 👉 https://t.co/tIZet0x2Id

[YNP of ERA @ynptweets]

1/ New thread on recently published @CKJsocial paper by @luisloureiro4 using target trial emulation to assess impact of arteriovenous fistula 🩸 formation on kidney function decline 📉

Link 👉 https://t.co/jadEyoAlCe

🧵by @richard_shemilt

[Balazs Odler @odlerb]

@AKronbichler, @WLASZ

[Balazs Odler @odlerb]

Recently, post-hoc analyses of the PEXIVAS trial have provided new insights into the use of PLEX in #AAV. In this viewpoint, we highlight clinical scenarios where its use may be benefical. Don’t miss „Viewpoint 1“ by Mike Walsh.

https://t.co/0lwAUHg6cA

[Balazs Odler @odlerb]

Check out our newest paper on a practical approach to common nephrology consultations. 👇🏻

Great job @KollandMichael, @saberger_ , @alehkir ! 👌🏻

https://t.co/agnTo5Bjhx

[Kidney International @Kidney_Int]

The effects of #plasmaexchange and #glucocorticoids on early kidney function among patients with #ANCA-associated #vasculitis in the PEXIVAS trial

https://t.co/MyvNH331fR

#OpenAccess #glomerulonephritis #ESKD

[Laurent ARNAUD @Lupusreference]

✅ Let's see who will bring forward the best arguments 😏😇 #Lupus nephritis - standard of care (for all, will already be something)

[Kidney International @Kidney_Int]

Lupus nephritis: redefining the treatment goals

https://t.co/EGi9RYjl9w

#KIEditorial #OpenAccess #lupusnephritis
@MayoClinicNeph @MayoClinicPath

[ANZ Vasculitis Society, '26 Vasculitis Wkshop host @anzvasc]

Website's up!
https://t.co/aVu5qXrbd4
All things #vasculitis in Melbourne Feb 2026. Key dates, things to do and promotional tools, with more to follow
Come for exceptional research, learning and interactions over 5 days
And....a great trip to Australia and New Zealand!

[YNP of ERA @ynptweets]

👀 Check our new snapshot summary on fluid removal targets during intermittent renal replacement therapy for AKI!

https://t.co/MdToC3TlsH

@WBeaubien is the YNP author.

Prepared by @smirioglu.

@ERAkidney @CKJsocial